# Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

> **NCT00032188** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (actual)

## Conditions studied

- Recurrent Renal Cell Cancer
- Stage III Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **DRUG:** bryostatin 1
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00032188
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2006-06
- **Final completion:** —
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00032188

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00032188, "Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00032188. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*